Daniel Fernandez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Daniel Fernandez has a total of 341 co-authors. Here are the top co-authors by number of shared publications:
- Brendan G. Dwyer
Department of Chemical and Systems Biology, ChEM-H, and Stanford Cancer Institute, Stanford School of Medicine
17 shared publications - Calvin J. Kuo
Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, USA
17 shared publications - Cesar Guzman Huancas
Stanford Cancer Institute, Stanford, California
17 shared publications - Christine Wenjie Zhou
Stanford Cancer Institute, Stanford, California
17 shared publications - Gianna M. Colombo
Stanford School of Medicine
17 shared publications - Gregory W. Charville
Stanford University School of Medicine
17 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (20) , 23428-23448
Development of Next-Generation ALDH1B1 Inhibitors with Enhanced Pharmacological and Functional Properties
ALDH1B1 is a mitochondrial aldehyde dehydrogenase required for the survival of stem-like colorectal and pancreatic cancer cells. Isoform-selective guanidinyl antagonists of aldehyde dehydrogenases (IGUANAs) have been developed for ALDH1B1, and here we describe structure−activity relationship (SAR) studies of three scaffold components: the bicyclic guanidine core, a substituted aryl ring that engages the catalytic site, and a biaryl group that interacts with flanking residues. We further show that previously reported IGUANAs are metabolically labile and rapidly effluxed from intestinal epithelial cells. To address these limitations, we have explored bioisosteres of the biaryl moiety and modifications of the guanidine core. These investigations have yielded the aryl-alkyl ether derivative IGUANA-5, a potent ALDH1B1 inhibitor that selectively blocks the growth of colon and pancreatic cancer spheroids and exhibits enhanced in vitro and in vivo pharmacological properties. Our findings establish a new class of ALDH1B1 inhibitors that could inform the advancement of anti-cancer therapies.
- 9 October 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (20) , 23428-23448
Open AccessDevelopment of Next-Generation ALDH1B1 Inhibitors with Enhanced Pharmacological and Functional Properties
ALDH1B1 is a mitochondrial aldehyde dehydrogenase required for the survival of stem-like colorectal and pancreatic cancer cells. Isoform-selective guanidinyl antagonists of aldehyde dehydrogenases (IGUANAs) have been developed for ALDH1B1, and here we describe structure−activity relationship (SAR) studies of three scaffold components: the bicyclic guanidine core, a substituted aryl ring that engages the catalytic site, and a biaryl group that interacts with flanking residues. We further show that previously reported IGUANAs are metabolically labile and rapidly effluxed from intestinal epithelial cells. To address these limitations, we have explored bioisosteres of the biaryl moiety and modifications of the guanidine core. These investigations have yielded the aryl-alkyl ether derivative IGUANA-5, a potent ALDH1B1 inhibitor that selectively blocks the growth of colon and pancreatic cancer spheroids and exhibits enhanced in vitro and in vivo pharmacological properties. Our findings establish a new class of ALDH1B1 inhibitors that could inform the advancement of anti-cancer therapies.
- Open Access
- 27 May 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (7) , 113206
Structural basis for selective thymidine binding by the Borrelia burgdorferi substrate-binding protein BmpA
- 27 May 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (7) , 113206
Open AccessStructural basis for selective thymidine binding by the Borrelia burgdorferi substrate-binding protein BmpA
- Open Access
- 15 May 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Development of next-generation ALDH1B1 inhibitors with enhanced pharmacological and functional properties
ALDH1B1, a mitochondrial aldehyde dehydrogenase, is required for the survival of stem-like colorectal and pancreatic cancer cells and a promising drug target. Isoform-specific guanidinyl agonists of aldehyde dehydrogenases (IGUANAs) have been developed for ALDH1B1, and here we describe structure-activity relationship (SAR) studies of this scaffold. Our findings delineate three ligand domains and their individual SAR profiles: the bicyclic guanidine core, a substituted aryl ring that engages the catalytic site, and a biaryl group that interacts with flanking residues. We further show that previously reported IGUANAs are metabolically labile and rapidly effluxed from intestinal epithelial cells. To address these pharmacological limitations, we have explored bioisosteres of the biaryl moiety and modifications of the bicyclic guanidine core. These investigations have yielded next-generation IGUANAs that retain nanomolar potencies against ALDH1B1 while achieving enhanced metabolic stability and functional specificity. Our lead compound, IGUANA-5, is an aryl-alkyl ether derivative that selectively blocks the growth of colon and pancreatic cancer spheroids and exhibits reduced clearance and increased Cmax in mice. We have also used IGUANA-5 to elucidate the ALDH1B1-dependent transcriptome in pancreatic cancer cells, corroborating previous findings that ALDH1B1 promotes mitochondrial metabolism. Our findings establish aryl-alkyl ether-functionalized guanidines as a new class of ALDH1B1 inhibitors that could advance the development of new anti-cancer therapies.
- 15 May 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDevelopment of next-generation ALDH1B1 inhibitors with enhanced pharmacological and functional properties
ALDH1B1, a mitochondrial aldehyde dehydrogenase, is required for the survival of stem-like colorectal and pancreatic cancer cells and a promising drug target. Isoform-specific guanidinyl agonists of aldehyde dehydrogenases (IGUANAs) have been developed for ALDH1B1, and here we describe structure-activity relationship (SAR) studies of this scaffold. Our findings delineate three ligand domains and their individual SAR profiles: the bicyclic guanidine core, a substituted aryl ring that engages the catalytic site, and a biaryl group that interacts with flanking residues. We further show that previously reported IGUANAs are metabolically labile and rapidly effluxed from intestinal epithelial cells. To address these pharmacological limitations, we have explored bioisosteres of the biaryl moiety and modifications of the bicyclic guanidine core. These investigations have yielded next-generation IGUANAs that retain nanomolar potencies against ALDH1B1 while achieving enhanced metabolic stability and functional specificity. Our lead compound, IGUANA-5, is an aryl-alkyl ether derivative that selectively blocks the growth of colon and pancreatic cancer spheroids and exhibits reduced clearance and increased Cmax in mice. We have also used IGUANA-5 to elucidate the ALDH1B1-dependent transcriptome in pancreatic cancer cells, corroborating previous findings that ALDH1B1 promotes mitochondrial metabolism. Our findings establish aryl-alkyl ether-functionalized guanidines as a new class of ALDH1B1 inhibitors that could advance the development of new anti-cancer therapies.
- Open Access
- 14 December 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Development of next-generation ALDH1B1 inhibitors with enhanced pharmacological and functional properties
ALDH1B1, a mitochondrial aldehyde dehydrogenase, is required for the survival of stem-like colorectal and pancreatic cancer cells and a promising drug target. Isoform-specific guanidinyl agonists of aldehyde dehydrogenases (IGUANAs) have been developed for ALDH1B1, and here we describe structure-activity relationship (SAR) studies of this scaffold. Our findings delineate three ligand domains and their individual SAR profiles: the bicyclic guanidine core, a substituted aryl ring that engages the catalytic site, and a biaryl group that interacts with flanking residues. We further show that previously reported IGUANAs are metabolically labile and rapidly effluxed from intestinal epithelial cells. To address these pharmacological limitations, we have explored bioisosteres of the biaryl moiety and modifications of the bicyclic guanidine core. These investigations have yielded next-generation IGUANAs that retain nanomolar potencies against ALDH1B1 while achieving enhanced metabolic stability and functional specificity. Our lead compound, IGUANA-5, is an aryl-alkyl ether derivative that selectively blocks the growth of colon and pancreatic cancer spheroids and exhibits reduced clearance and increased Cmax in mice. We have also used IGUANA-5 to elucidate the ALDH1B1-dependent transcriptome in pancreatic cancer cells, corroborating previous findings that ALDH1B1 promotes mitochondrial metabolism. Our findings establish aryl-alkyl ether-functionalized guanidines as a new class of ALDH1B1 inhibitors that could advance the development of new anti-cancer therapies.
- 14 December 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDevelopment of next-generation ALDH1B1 inhibitors with enhanced pharmacological and functional properties
ALDH1B1, a mitochondrial aldehyde dehydrogenase, is required for the survival of stem-like colorectal and pancreatic cancer cells and a promising drug target. Isoform-specific guanidinyl agonists of aldehyde dehydrogenases (IGUANAs) have been developed for ALDH1B1, and here we describe structure-activity relationship (SAR) studies of this scaffold. Our findings delineate three ligand domains and their individual SAR profiles: the bicyclic guanidine core, a substituted aryl ring that engages the catalytic site, and a biaryl group that interacts with flanking residues. We further show that previously reported IGUANAs are metabolically labile and rapidly effluxed from intestinal epithelial cells. To address these pharmacological limitations, we have explored bioisosteres of the biaryl moiety and modifications of the bicyclic guanidine core. These investigations have yielded next-generation IGUANAs that retain nanomolar potencies against ALDH1B1 while achieving enhanced metabolic stability and functional specificity. Our lead compound, IGUANA-5, is an aryl-alkyl ether derivative that selectively blocks the growth of colon and pancreatic cancer spheroids and exhibits reduced clearance and increased Cmax in mice. We have also used IGUANA-5 to elucidate the ALDH1B1-dependent transcriptome in pancreatic cancer cells, corroborating previous findings that ALDH1B1 promotes mitochondrial metabolism. Our findings establish aryl-alkyl ether-functionalized guanidines as a new class of ALDH1B1 inhibitors that could advance the development of new anti-cancer therapies.
- Open Access
- 11 December 2025
- Published by AIP Publishing in The Journal of Chemical Physics
- Vol. 163 (22)
Repetitive proteins that undergo large conformational changes evade structural prediction algorithms
Protein structure prediction algorithms, such as AlphaFold, have accelerated protein design and advanced the understanding of the relationship between amino acid sequence and protein structure. However, these algorithms are limited in their ability to predict the structures of conformationally dynamic, intrinsically disordered, and stimuli-responsive proteins. To evaluate sequence-to-structure predictions of such challenging proteins, we explored a class of conformationally dynamic, repeats-in-toxin (RTX) proteins. RTX proteins adopt intrinsically disordered conformations in the absence of calcium and undergo reversible folding into β-roll structures upon binding to calcium. RTX proteins are characterized by tandem repeats of the sequence GGXGXDXUX, in which X can be any amino acid and U is an aliphatic amino acid. We designed RTX sequence variants with global substitutions of nonconserved amino acids, tandem repeats of consensus sequences GGAGXDTLY, and tandem repeats of scrambled sequences GGAGXDTYL. AlphaFold2 and AlphaFold3 predicted that all of these RTX variants adopt β-roll structures, characteristic of wild-type RTX bound to calcium. However, modeling the predicted structures with molecular dynamics simulations and characterizing the protein variants with circular dichroism spectroscopy, small-angle x-ray scattering, and x-ray crystallography revealed that variants adopt diverse, sequence-dependent structures in the absence and presence of calcium. To better design proteins for applications in biotechnology and sustainability, it is critical to build predictive tools that consider intrinsically disordered protein states and validate these tools with multi-mode, multi-scale experimental data.
- 11 December 2025
- Published by AIP Publishing in The Journal of Chemical Physics
- Vol. 163 (22)
Open AccessRepetitive proteins that undergo large conformational changes evade structural prediction algorithms
Protein structure prediction algorithms, such as AlphaFold, have accelerated protein design and advanced the understanding of the relationship between amino acid sequence and protein structure. However, these algorithms are limited in their ability to predict the structures of conformationally dynamic, intrinsically disordered, and stimuli-responsive proteins. To evaluate sequence-to-structure predictions of such challenging proteins, we explored a class of conformationally dynamic, repeats-in-toxin (RTX) proteins. RTX proteins adopt intrinsically disordered conformations in the absence of calcium and undergo reversible folding into β-roll structures upon binding to calcium. RTX proteins are characterized by tandem repeats of the sequence GGXGXDXUX, in which X can be any amino acid and U is an aliphatic amino acid. We designed RTX sequence variants with global substitutions of nonconserved amino acids, tandem repeats of consensus sequences GGAGXDTLY, and tandem repeats of scrambled sequences GGAGXDTYL. AlphaFold2 and AlphaFold3 predicted that all of these RTX variants adopt β-roll structures, characteristic of wild-type RTX bound to calcium. However, modeling the predicted structures with molecular dynamics simulations and characterizing the protein variants with circular dichroism spectroscopy, small-angle x-ray scattering, and x-ray crystallography revealed that variants adopt diverse, sequence-dependent structures in the absence and presence of calcium. To better design proteins for applications in biotechnology and sustainability, it is critical to build predictive tools that consider intrinsically disordered protein states and validate these tools with multi-mode, multi-scale experimental data.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Tables S1-S11 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Supporting data for PRISM cell viability screens, CRISPR screens, oligonucleotide cloning, RNA-seq profiling, base editor screens, crystallography, and proteomics.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTables S1-S11 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Supporting data for PRISM cell viability screens, CRISPR screens, oligonucleotide cloning, RNA-seq profiling, base editor screens, crystallography, and proteomics.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S11 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Depicts live-cell imaging, lethal fraction analyses, and protein interaction/immunoblot assays demonstrating TRIM21-dependent PRLX-induced nucleoporin destabilization and rapid cancer cell death.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Depicts live-cell imaging, lethal fraction analyses, and protein interaction/immunoblot assays demonstrating TRIM21-dependent PRLX-induced nucleoporin destabilization and rapid cancer cell death.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Demonstrates JWZ-8-103-induced increases in TRIM21 thermal stability in PANC-1 lysates by CETSA, including quantification and immunoblot analysis.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Demonstrates JWZ-8-103-induced increases in TRIM21 thermal stability in PANC-1 lysates by CETSA, including quantification and immunoblot analysis.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Shows transcriptomic and protein analyses demonstrating TRIM21-dependent NFκB activation by PRLX, including mRNA-seq, GSEA, confocal imaging, and subcellular fractionation immunoblots.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Shows transcriptomic and protein analyses demonstrating TRIM21-dependent NFκB activation by PRLX, including mRNA-seq, GSEA, confocal imaging, and subcellular fractionation immunoblots.